Clinical and prognostic role of circulating MMP-2 and its inhibitor TIMP-2 in HCC patients prior to and after trans-hepatic arterial chemo-embolization

Clinical Biochemistry
Antonella DanieleVito Fazio

Abstract

Trans-hepatic arterial chemo-embolization is the most commonly used treatment for unresectable hepatocellular carcinoma. The prognostic impact of tumor biomarkers has not therefore been evaluated in this treatment. Imbalance between matrix metalloproteinase-2 and tissue inhibitor metalloproteinase-2 is considered to play an important role in extracellular matrix remodeling and degradation. Higher serum levels of MMP-2 have been shown to predict a poor prognosis and shorter overall survival in HCC after TACE. The objective of this study was to evaluate the serum levels of MMP-2 and TIMP-2 in HCC patients before and after TACE to evaluate their clinical significance and usefulness as prognostic biomarkers. MMP-2 and TIMP-2 levels were measured by ELISA in 75 HCC patients and 30 healthy controls. Sera MMP-2 and TIMP-2 were correlated with clinico-pathological features. The mean serum MMP-2 and TIMP-2 levels of HCC patients before TACE were 1700±71ng/mL and 89±45ng/mL respectively, significantly higher than that of the control group: 771±60ng/mL (p<0.0001, t-test) and 25.7±20ng/mL respectively (p<0.0001, t-test). A significant decrease of MMP-2 levels after 1 and 3months compared to baseline time was observed (p<0.0001), while with...Continue Reading

References

Aug 1, 1973·The British Journal of Surgery·R N PughR Williams
Mar 1, 1995·Hepatology : Official Journal of the American Association for the Study of Liver Diseases·T TakaharaA Watanabe
Oct 1, 1994·Pathology, Research and Practice·M J Arthur
Sep 1, 1993·Journal of Gastroenterology and Hepatology·D A MuzzilloT Hayakawa
Jan 1, 1997·Critical Reviews in Eukaryotic Gene Expression·P Borden, R A Heller
Oct 13, 1999·Seminars in Liver Disease·J M LlovetJ Bruix
Oct 23, 2001·International Journal of Cancer. Journal International Du Cancer·K A McGlynnJ F Fraumeni
Jan 22, 2002·International Journal of Cancer. Journal International Du Cancer·Gianluigi GiannelliSalvatore Antonaci
Mar 1, 2002·Hepatology : Official Journal of the American Association for the Study of Liver Diseases·Jordi Bruix, Josep M Llovet
Mar 20, 2002·Nature Reviews. Cancer·M J Bissell, D Radisky
May 1, 2002·Hepatology : Official Journal of the American Association for the Study of Liver Diseases·Chung-Mau LoJohn Wong
May 7, 2002·Nature Reviews. Cancer·Mikala Egeblad, Zena Werb
Jan 24, 2003·Hepatology : Official Journal of the American Association for the Study of Liver Diseases·Josep M Llovet, Jordi Bruix
Dec 12, 2003·Lancet·Josep M LlovetJordi Bruix
Mar 26, 2004·Cancer Letters·André Nkondjock, Parviz Ghadirian
Jan 26, 2010·Journal of Vascular and Interventional Radiology : JVIR·Antonio NicoliniAngelo Sangiovanni
Sep 14, 2011·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Timothy M PawlikJean-Francois H Geschwind
Aug 8, 2013·Annals of Oncology : Official Journal of the European Society for Medical Oncology·C BosettiC La Vecchia

❮ Previous
Next ❯

Citations

Jun 9, 2016·The International Journal of Biochemistry & Cell Biology·A DanieleR Divella
Aug 28, 2017·Journal of Molecular Medicine : Official Organ of the Gesellschaft Deutscher Naturforscher Und Ärzte·Bonan LinJiaqiang Huang
Nov 25, 2016·Experimental and Therapeutic Medicine·Wanfu LinChangquan Ling
Dec 31, 2019·Analytical Cellular Pathology (Amsterdam)·Cristian ScheauMonica Neagu
Jul 11, 2020·Hepatic Oncology·Jiuliang YanQinghai Ye

❮ Previous
Next ❯

Related Concepts

Related Feeds

Carcinoma, Hepatocellular

Hepatocellular Carcinoma is a malignant cancer in liver epithelial cells. Discover the latest research on Hepatocellular Carcinoma here.